Tesamorelin Research Dosage: Published Protocol Reference
Tesamorelin dosage references vary by route and study context. The database lists Subcutaneous injection: 2 mg, Once daily. These are research-context references, not a universal protocol.
Direct Answer
Tesamorelin is FDA-approved for HIV-related lipodystrophy and has the strongest human evidence of any GHRH analog in this library - multiple Phase 3 RCTs demonstrating significant visceral fat reduction. Outside its approved indication, human data is limited. For research into GHRH-pathway GH stimulation, tesamorelin provides the reference standard with actual regulatory approval behind it.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Growth Hormone
- Best for
- HIV-associated lipodystrophy, visceral fat reduction, GHRH-mediated GH research
Research Dosage References
- <strong>Subcutaneous injection</strong> - 2 mg - Once daily - FDA-approved dose for HIV-associated lipodystrophy. Injected into the abdomen. Should be administered on an empty stomach or at bedtime.
Half-Life
26-38 minutes (but GH release effects last several hours).
Evidence Limits
Dosage entries are compiled from labels, published studies, and research-context references where available. For Tesamorelin, the evidence grade is Level A, and the current research status is FDA Approved.
Safety Signals
- Contraindicated in patients with active malignancy
- Disruption of the hypothalamic-pituitary axis from hypophysectomy, hypopituitarism, or pituitary tumor surgery
- Known hypersensitivity to tesamorelin or mannitol
- Should not be used during pregnancy
- May cause fluid retention and glucose intolerance
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | Visceral Adipose Tissue Reduction (Level A), IGF-1 Increase (Level A), and Cognitive Function (Level B) |
| Primary citation count | 3 |
| Last reviewed | 2026-06-02 |
Related Guides
How to Cite This Page
ExaminePeptides. "Tesamorelin Research Dosage: Published Protocol Reference." Last reviewed 2026-06-02. https://examinepeptides.com/answers/tesamorelin-research-dosage/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.